Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: an international network cohort study

Markus, Aniek F.; Strauss, Victoria Y.; Burn, Edward; Li, Xintong; Delmestri, Antonella; Reich, Christian; Yin, Can; Mayer, Miguel Ángel, 1960-; Ramírez Anguita, Juan Manuel; Marti, Edelmira; Verhamme, Katia M. C.; Rijnbeek, Peter; Prieto-Alhambra, Daniel; Jödicke, Annika M.

doi:http://dx.doi.org/10.3389/fphar.2023.1118203

Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: an international network cohort study

License

Citation

Markus AF, Strauss VY, Burn E, Li X, Delmestri A, Reich C, Yin C, Mayer MA, Ramírez-Anguita JM, Marti E, Verhamme MC, Rijnbeek PR, Prieto-Alhambra D, Jödicke AM. Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: an international network cohort study. Front Pharmacol. 2023;14:1118203. DOI: 10.3389/fphar.2023.1118203

Abstract

Background: Thrombosis with thrombocytopenia syndrome (TTS) has been identified as a rare adverse event following some COVID-19 vaccines. Various guidelines have been issued on the treatment of TTS. We aimed to characterize the treatment of TTS and other thromboembolic events (venous thromboembolism (VTE), and arterial thromboembolism (ATE) after COVID-19 vaccination and compared to historical (pre-vaccination) data in Europe and the US. Methods: We conducted an international network cohort study using 8 primary care, outpatient, and inpatient databases from France, Germany, Netherlands, Spain, The United Kingdom, and The United States. We investigated treatment pathways after the diagnosis of TTS, VTE, or ATE for a pre-vaccination (background) cohort (01/2017-11/2020), and a vaccinated cohort of people followed for 28 days after a dose of any COVID-19 vaccine recorded from 12/2020 onwards). Results: Great variability was observed in the proportion of people treated (with any recommended therapy) across databases, both before and after vaccination. Most patients with TTS received heparins, platelet aggregation inhibitors, or direct Xa inhibitors. The majority of VTE patients (before and after vaccination) were first treated with heparins in inpatient settings and direct Xa inhibitors in outpatient settings. In ATE patients, treatments were also similar before and after vaccinations, with platelet aggregation inhibitors prescribed most frequently. Inpatient and claims data also showed substantial heparin use. Conclusion: TTS, VTE, and ATE after COVID-19 vaccination were treated similarly to background events. Heparin use post-vaccine TTS suggests most events were not identified as vaccine-induced thrombosis with thrombocytopenia by the treating clinicians.